and its stock price could jump. So, in my view, Pfizer is the better option, except perhaps for high-risk, growth-oriented investors. Moderna has more upside if some of its pipeline candidates ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

but the stock is down 65% since my August rating downgrade. Despite pipeline progress, regulatory uncertainty and intense competition from Pfizer and GSK pose significant risks to Moderna's ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

On this episode of Stock Movers ... Vaccine stocks fall: Moderna -12%, Novavax -7%, BioNTech-8.0%, CureVac -7.2%, Vir Biotechnology -4.2%, Pfizer -1.6% - Tesla is leading losses among the ...

If it can continue lining up positive data readouts and regulatory approvals, its financial results will eventually improve, and its stock price could jump. Pfizer and Moderna are very different ...

Vaccine developers were hit hardest by the news. Moderna (MRNA) stock dropped nearly 10% following the resignation news. While Pfizer’s portfolio is more diversified than Moderna’s ...

However, Pfizer and Moderna's revenue and earnings dropped ... Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the past ...